Poly(carboxybetaine) lipids enhance mRNA therapeutics efficacy and reduce their immunogenicity
Source abstract
Abstract
Messenger RNA (mRNA) therapeutics are a promising strategy to combat diverse diseases. Traditional lipid nanoparticle (LNP) formulations for mRNA delivery contain poly(ethylene) glycol (PEG), a polymer widely used in drug delivery carriers but that recently has been associated with efficacy and immunogenicity concerns. Here we report poly(carboxybetaine) (PCB) lipids as surrogates for PEG-lipids used in mRNA formulations. In vitro studies with immortalized and primary cells show that PCB-containing LNPs have higher mRNA transfection efficiency than PEG-containing LNPs across different formulations. Moreover, primary cell engineering and in vivo immunization studies in mice further demonstrate greater therapeutic efficacy of PCB-containing LNPs over their PEG counterparts. Mechanistic assays show that this improvement is attributed to enhanced endosomal escape of PCB-containing LNPs. These formulations exhibit a safe immunotoxicity profile and effectively mitigate the accelerated blood clearance effect that has been observed for PEG-containing LNPs, enabling repeated administrations without efficacy loss. Overall, these findings highlight PCB-containing LNPs as a potent and safe mRNA delivery platform for clinical applications.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Virus-based gene therapy research · Orthopedic Infections and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (52)
Show source-provided references
1. Cullis, P. R. & Hope, M. J. Lipid nanoparticle systems for enabling gene therapies. Mol. Ther. 25, 1467–1475 (2017).10.1016/j.ymthe.2017.03.013 ↗
2. Mullard, A. COVID-19 vaccine success enables a bolder vision for mRNA cancer vaccines, says BioNTech CEO. Nat. Rev. Drug Discov. 20, 500–501 (2021).10.1038/d41573-021-00110-x ↗
3. Hou, X., Zaks, T., Langer, R. & Dong, Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078–1094 (2021).10.1038/s41578-021-00358-0 ↗
4. Akinc, A. et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat. Nanotechnol. 14, 1084–1087 (2019).10.1038/s41565-019-0591-y ↗
5. Hassett, K. J. et al. Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines. Mol. Ther. Nucleic Acids 15, 1–11 (2019).10.1016/j.omtn.2019.01.013 ↗
6. Schoenmaker, L. et al. mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability. Int. J. Pharm. 601, 120586 (2021).10.1016/j.ijpharm.2021.120586 ↗
7. Zhang, P., Sun, F., Liu, S. & Jiang, S. Anti-PEG antibodies in the clinic: current issues and beyond PEGylation. J. Control. Release 244, 184–193 (2016).10.1016/j.jconrel.2016.06.040 ↗
8. Kumar, V. et al. Shielding of lipid nanoparticles for siRNA delivery: impact on physicochemical properties, cytokine induction, and efficacy. Mol. Ther. Nucleic Acids 3, e210 (2014).10.1038/mtna.2014.61 ↗
9. Yang, Q. et al. Analysis of pre-existing IgG and IgM antibodies against polyethylene glycol (PEG) in the general population. Anal. Chem. 88, 11804–11812 (2016).10.1021/acs.analchem.6b03437 ↗
10. Besin, G. et al. Accelerated blood clearance of lipid nanoparticles entails a biphasic humoral response of B-1 followed by B-2 lymphocytes to distinct antigenic moieties. Immunohorizons 3, 282–293 (2019).10.4049/immunohorizons.1900029 ↗
11. Sanchez, A. et al. Substituting poly(ethylene glycol) lipids with poly(2-ethyl-2-oxazoline) lipids improves lipid nanoparticle repeat dosing. Adv. Health. Mater. 13, e2304033 (2024).10.1002/adhm.202304033 ↗
12. Ju, Y. et al. Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine. ACS Nano 16, 11769–11780 (2022).10.1021/acsnano.2c04543 ↗
13. Vrieze, J. Suspicions grow that nanoparticles in Pfizer’s COVID-19 vaccine trigger rare allergic reactions. Science https://www.science.org/content/article/suspicions-grow-nanoparticles-pfizer-s-covid-19-vaccine-trigger-rare-allergic-reactions (21 December 2020).
14. Kang, D. D. et al. Engineering LNPs with polysarcosine lipids for mRNA delivery. Bioact. Mater. 37, 86–93 (2024).
15. Nogueira, S. S. et al. Polysarcosine-functionalized lipid nanoparticles for therapeutic mRNA delivery. ACS Appl. Nano Mater. 3, 10634–10645 (2020).10.1021/acsanm.0c01834 ↗
16. Cao, Z., Zhang, L. & Jiang, S. Superhydrophilic zwitterionic polymers stabilize liposomes. Langmuir 28, 11625–11632 (2012).10.1021/la302433a ↗
17. Li, Y. et al. Enhanced endosomal/lysosomal escape by distearoyl phosphoethanolamine-polycarboxybetaine lipid for systemic delivery of siRNA. J. Control. Release 176, 104–114 (2014).10.1016/j.jconrel.2013.12.007 ↗
18. Li, Q. et al. Zwitterionic biomaterials. Chem. Rev. 122, 17073–17154 (2022).10.1021/acs.chemrev.2c00344 ↗
19. Li, B. et al. Zwitterionic nanocages overcome the efficacy loss of biologic drugs. Adv. Mater. 30, e1705728 (2018).
20. Keefe, A. J. & Jiang, S. Poly(zwitterionic)protein conjugates offer increased stability without sacrificing binding affinity or bioactivity. Nat. Chem. 4, 59–63 (2011).10.1038/nchem.1213 ↗
21. Li, B. et al. Revealing the immunogenic risk of polymers. Angew. Chem. Int. Ed. 57, 13873–13876 (2018).10.1002/anie.201808615 ↗
22. Wang, X. et al. Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery. Nat. Protoc. 18, 265–291 (2023).10.1038/s41596-022-00755-x ↗
23. Dong, Y. et al. Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates. Proc. Natl Acad. Sci. USA 111, 3955–3960 (2014).10.1073/pnas.1322937111 ↗
24. Kumar, A. R. K., Shou, Y., Chan, B., L, K. & Tay, A. Materials for improving immune cell transfection. Adv. Mater. 33, e2007421 (2021).
25. Patel, S. et al. Beyond CAR T cells: other cell-based immunotherapeutic strategies against cancer. Front. Oncol. 9, 196 (2019).10.3389/fonc.2019.00196 ↗
26. Weber, E. W., Maus, M. V. & Mackall, C. L. The emerging landscape of immune cell therapies. Cell 181, 46–62 (2020).10.1016/j.cell.2020.03.001 ↗
27. Jahan, F. et al. Using the Jurkat reporter T cell line for evaluating the functionality of novel chimeric antigen receptors. Front. Mol. Med. 3, 1070384 (2023).10.3389/fmmed.2023.1070384 ↗
28. Chang, Y. et al. CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy. Nat. Commun. 14, 2266 (2023).
29. Ren, J. et al. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin. Cancer Res. 23, 2255–2266 (2017).10.1158/1078-0432.CCR-16-1300 ↗
30. Barbier, A. J., Jiang, A. Y., Zhang, P., Wooster, R. & Anderson, D. G. The clinical progress of mRNA vaccines and immunotherapies. Nat. Biotechnol. 40, 840–854 (2022).10.1038/s41587-022-01294-2 ↗
31. Kreiter, S. et al. Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals. J. Immunol. 180, 309–318 (2008).10.4049/jimmunol.180.1.309 ↗
32. Yanez Arteta, M. et al. Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles. Proc. Natl Acad. Sci. USA 115, E3351–E3360 (2018).10.1073/pnas.1720542115 ↗
33. Aburai, K., Hatanaka, K., Takano, S., Fujii, S. & Sakurai, K. Characterizing an siRNA-containing lipid-nanoparticle prepared by a microfluidic reactor: small-angle X-ray scattering and cryotransmission electron microscopic studies. Langmuir 36, 12545–12554 (2020).10.1021/acs.langmuir.0c01079 ↗
34. Patel, S. et al. Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA. Nat. Commun. 11, 983 (2020).
35. Cornebise, M. et al. Discovery of a novel amino lipid that improves lipid nanoparticle performance through specific interactions with mRNA. Adv. Funct. Mater. 32, 2106727 (2022).10.1002/adfm.202106727 ↗
36. Leung, A. K. et al. Lipid nanoparticles containing siRNA synthesized by microfluidic mixing exhibit an electron-dense nanostructured core. J. Phys. Chem. C 116, 18440–18450 (2012).10.1021/jp303267y ↗
37. Cheng, M. H. Y. et al. Induction of bleb structures in lipid nanoparticle formulations of mRNA leads to improved transfection potency. Adv. Mater. 35, e2303370 (2023).
38. Dammes, N. et al. Conformation-sensitive targeting of lipid nanoparticles for RNA therapeutics. Nat. Nanotechnol. 16, 1030–1038 (2021).10.1038/s41565-021-00928-x ↗
39. Sedic, M. et al. Safety evaluation of lipid nanoparticle-formulated modified mRNA in the Sprague-Dawley rat and cynomolgus monkey. Vet. Pathol. 55, 341–354 (2018).10.1177/0300985817738095 ↗
40. Vlatkovic, I. Non-immunotherapy application of LNP-mRNA: maximizing efficacy and safety. Biomedicines 9, 530 (2021).10.3390/biomedicines9050530 ↗
41. Liang, F. et al. Efficient targeting and activation of antigen-presenting cells in vivo after modified mRNA vaccine administration in rhesus macaques. Mol. Ther. 25, 2635–2647 (2017).10.1016/j.ymthe.2017.08.006 ↗
42. Chaudhary, N. et al. Amine headgroups in ionizable lipids drive immune responses to lipid nanoparticles by binding to the receptors TLR4 and CD1d. Nat. Biomed. Eng 8, 1483–1498 (2024).10.1038/s41551-024-01256-w ↗
43. Schlich, M. et al. Cytosolic delivery of nucleic acids: the case of ionizable lipid nanoparticles. Bioeng Transl. Med. 6, e10213 (2021).10.1002/btm2.10213 ↗
44. Bruininks, B. M., Souza, P. C., Ingolfsson, H. & Marrink, S. J. A molecular view on the escape of lipoplexed DNA from the endosome. eLife 9, e52012 (2020).10.7554/eLife.52012 ↗
45. Liu, S. & Jiang, S. Zwitterionic polymer-protein conjugates reduce polymer-specific antibody response. Nano Today 11, 285–291 (2016).10.1016/j.nantod.2016.05.006 ↗
46. Kochenderfer, J. N. et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116, 4099–4102 (2010).10.1182/blood-2010-04-281931 ↗
47. Henderson, J. M. et al. Cap 1 messenger RNA synthesis with co-transcriptional CleanCap® analog by in vitro transcription. Curr. Protoc. 1, e39 (2021).
48. Nance, K. D. & Meier, J. L. Modifications in an emergency: the role of N1-methylpseudouridine in COVID-19 vaccines. ACS Cent. Sci. 7, 748–756 (2021).10.1021/acscentsci.1c00197 ↗
49. Hopkins, J. B., Gillilan, R. E. & Skou, S. BioXTAS RAW: improvements to a free open-source program for small-angle X-ray scattering data reduction and analysis. J. Appl. Crystallogr. 50, 1545–1553 (2017).10.1107/S1600576717011438 ↗
50. Luozhong, S. et al. Phosphatidylserine lipid nanoparticles promote systemic RNA delivery to secondary lymphoid organs. Nano Lett. 22, 8304–8311 (2022).10.1021/acs.nanolett.2c03234 ↗
51. Nelson, J. et al. Impact of mRNA chemistry and manufacturing process on innate immune activation. Sci. Adv. 6, eaaz6893 (2020).
52. Baiersdorfer, M. et al. A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA. Mol. Ther. Nucleic Acids 15, 26–35 (2019).10.1016/j.omtn.2019.02.018 ↗